
Opinion|Videos|December 20, 2024
Dosing Frequency, and Adverse Event Management With Bispecific Therapy
Panelists discuss how an early adverse event for this drug class no matter what the mechanism or target is, is cytokine release syndrome (CRS), and it tends to occur on a timescale that is predictable. When treating patients in the outpatient setting, they receive dexamethasone, given at the first fever, which is the first sign of cytokine release syndrome (CRS) and helps mitigate it.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the CRS and ICANS that we see with the bispecifics, both BCMA and GPRC5D, and how we are approaching treating these patients in the inpatient and outpatient setting?
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
3
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
4
Balancing Oncologic Outcomes With Patient Priorities in Prostate Cancer Care
5





















































